Facebook
X
LinkedIn
ForwardInnovating Care: Targeting IL-33 and Epithelial Alarmins
Epithelial alarmin cytokines—particularly IL-33, IL-25, and TSLP—play a key role in driving inflammation and exacerbations in respiratory diseases such as COPD, asthma, and acute viral infections. Among these, IL-33 stands out for its dual role in type-2 immune responses and antiviral defense. Prominently expressed in lung epithelial cells, IL-33 amplifies inflammatory pathways during viral infections like influenza, RSV, and SARS-CoV-2. These mechanisms contribute to exacerbations in chronic lung diseases, including asthma and COPD. At the same time, IL-33 enhances antiviral immunity by promoting cytotoxic T-cell responses, highlighting its complexity as both a therapeutic target and biomarker. Understanding these interactions can lead to innovative therapeutic strategies and improved patient outcomes in respiratory disease management.
In this session, a powerhouse panel of pulmonologists, allergists/immunologists, and critical care specialists explores cutting-edge, multidisciplinary perspectives on IL-33 and other epithelial alarmins in chronic respiratory disease. Through real-world case discussions and interactive dialogue, the panel will unpack the evolving science behind airway inflammation and highlight how targeting these upstream mediators can transform personalized care.
Commercial Supporter: This activity is supported by an educational grant from AstraZeneca Pharmaceuticals.
Target Audience
Pulmonologists, Allergists/Immunologists, Critical Care Specialists, including Nurse Practitioners and Physician Assistants
Learning Objectives
1. Describe how IL-33, IL-25, and TSLP contribute to respiratory disease pathophysiology and exacerbations.
2. Identify the impact of viral infections on alarmin pathways and disease progression
3. Analyze the role of IL-33 in driving immune responses and inflammation.
4. Apply evidence-based strategies to manage respiratory diseases influenced by epithelial alarmins.
You may also be interested in
William Janssen, MD
Reilley Chair of Lung Injury, Repair and Interstitial Disease
Professor of Medicine
Section Head for Critical Care
Associate Vice President for Academic Affairs
National Jewish Health
Denver, Colorado
William Janssen, MD
Reilley Chair of Lung Injury, Repair and Interstitial Disease
Professor of Medicine
Section Head for Critical Care
Associate Vice President for Academic Affairs
National Jewish Health
Denver, Colorado
Katharine Woessner, MD, FAAAAI
Clinical Professor of Medicine
Division Head, Allergy, Asthma and Immunology
Scripps Clinic Medical Group
San Diego, California
Faculty Disclosures
Rohit Katial, MD, FAAAAI, FACAAI, FACP discloses the following relevant financial relationships:
Advisory Board: AstraZeneca, GlaxoSmithKline, Grifols, Sanofi Regeneron
Speaker: AstraZeneca, Grifols, Sanofi Regeneron
William Janssen, MD has no relevant financial relationships to disclose
Monica Kraft, MD discloses the following relevant financial relationships:
Advisory Board: AstraZeneca, Chiesi, Regeneron, Sanofi
Consultant: Kinaset
Investigator: Areteia
Speaker: AstraZeneca, Chiesi, Regeneron, Sanofi
Katharine Woessner, MD, FAAAAI discloses the following relevant financial relationships
Advisory Board: AstraZeneca, GlaxoSmithKline, Regeneron, Sanofi Aventis, Takeda
Consultant: AstraZeneca, GlaxoSmithKline
Speaker: Amgen, AstraZeneca, GlaxoSmithKline, Regeneron, Sanofi Aventis
All relevant financial relationships among individuals in a position to control the content of this activity have been identified and mitigated according to the Standards of Integrity and Independence in Accredited Continuing Education.
Disclaimer
National Jewish Health (“NJH”) and its officers, Board of Directors, faculty, employees, representatives, and other agents (collectively, “NJH Parties”) shall not be responsible in any capacity for, and do not warrant any content whatsoever, in any NJH publication or other product (in any medium), or the use or reliance on any such content, and expressly disclaim any and all liability for such content. All such responsibility for content and use of product solely rests with the authors or the advertisers, as the case may be.
By way of example, without limiting the foregoing, this disclaimer of liability applies to the accuracy, completeness, effectiveness, quality, appearance, ideas, or products, as the case may be, of or resulting from, any statements, references, articles, positions, claimed diagnosis, claimed possible treatments, services, or advertising, express or implied, contained in any NJH live meeting, publication, online course or other product.
Furthermore, the content should not be considered medical advice and is not intended to replace consultation with a qualified medical professional. Under no circumstances, including negligence, shall any of the NJH Parties be liable for any DIRECT, INDIRECT, INCIDENTAL, SPECIAL or CONSEQUENTIAL DAMAGES, or LOST PROFITS that result from any of the foregoing, regardless of legal theory and whether or not claimant was advised of the possibility of such damages.
Privacy Policy
The Office of Professional Education of National Jewish Health respects and values your privacy and the confidentiality of the information you choose to share with us. We are committed to protection of this information and will assure your privacy when participating in our Internet Continuing Medical Education (CME).
We do not collect any personal information about a visit unless that information is provided voluntarily. We may collect aggregate information on web pages visited in order to assess and improve the content of our Internet CME programming.
If you decide to register for an Internet CME program, we will collect personal information that you voluntarily share with us. We will only use this information to notify you of future National Jewish Health CME activities.
https://www.nationaljewish.org/education-training/pro-ed/privacy-policy-and-practices
myCME privacy policy
AMA PRA Category 1 CreditsTM
Accreditation Statement
National Jewish Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation
National Jewish Health designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the
evaluation component, enables the participant to earn up to 1.0 MOC points in
the American Board of Internal Medicine’s (ABIM) Maintenance of
Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Conflicts of Interest Disclosure Policy:
In accordance with the Accreditation Council for Continuing Medical Education (ACCME), National Jewish Health requires that all program faculty, content developers, reviewers, and others in a position to control the content of this activity disclose to learners the presence or absence of any relevant financial relationships with an ACCME-defined ineligible company within the preceding 24 months of the activity. The ACCME defines an “ineligible company” as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Our goal is to ensure that there is no compromise in the ethical relationship that exists between those in a position to control the content of the activity and those participating in the activity and their respective professional duties. All accredited education activities offered by National Jewish Health are reviewed to ensure a balanced and evidence-
Planners’ and Managers’ Disclosures
Meghan Brenner, MA has no relevant financial relationships to disclose.
Bryce Chitanavong, MBA has no relevant financial relationships to disclose.
Andrea Harshman, MHA, CHCP, CMP-HC has no relevant financial relationships to disclose.
Harold Nelson, MD has no relevant financial relationships to disclose.
All relevant financial relationships among individuals in a position to control the content of this activity have been identified and mitigated according to the Standards of Integrity and Independence in Accredited Continuing Education.
Disclosure of Unlabeled Use:
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.
No endorsement of unapproved products or uses is made or implied by coverage of these products or uses.
Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings
Available Credit
- 1.00 ABIM Medical Knowledge
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation